Developed by the WuXi AppTec Team

Overview of Global and Chinese Pharmaceutical and Healthcare Company Investment and Financing Cases Today!

Domestic Financing

On September 18, Hong Kong Asia Healthcare completed a $150 million strategic financing round, with General Atlantic as the investor.Hong Kong Asia Healthcare is the largest cardiovascular specialty chain group in China. Its subsidiaries include Wuhan Asia Heart Hospital (one of the largest specialized cardiac hospitals in China), Xinjiang Yaxin Cardiovascular Disease Hospital, and Wuhan Jiangcheng Yaxin Hospital, among other specialized hospitals, with a total bed capacity approaching 3,000.

September 18,Yimai Yangguang Completes RMB 130 Million Series B+ Financing Round, with Investors Including CICC Capital and Xiaofeng InvestmentYimai Yangguang is a third-party chain medical imaging service provider, specializing in the construction of medical imaging institutions, development of medical imaging technologies, and operational management. Its core businesses include the Yimai Yangguang Medical Imaging Cloud Service Platform, independent medical imaging centers, and the Yimai Yangguang Imaging Academy.

September 18,Jinhao Medical Completes NEEQ Financing.Jinhao Medical is a provider of smart medical devices, primarily offering healthcare products such as hearing aids, blood pressure monitors, pulse oximeters, nebulizers, and air mattresses. Its hearing aid product line includes digital hearing aids, open-fit hearing aids, and rechargeable hearing aids. The nebulizer range comprises piston nebulizers and ultrasonic mesh nebulizers. Pulse oximeters are available with either LED or OLED displays. The company provides comprehensive solutions in the field of smart medical devices for its users.

September 17,PharmaCube Completes Tens of Millions of RMB in Series A Financing,Investors include Legend Star, Chongde Investment, and Dynamic Balance Capital. PharmCube is an organization dedicated to the in-depth processing and standardized reconstruction of fundamental pharmaceutical data, covering the entire industry chain including drug R&D, registration, business development (BD), investment, and sales. Committed to interpreting, supporting, and leading the industry through data, PharmCube strives to promote a more efficient, transparent, and fair ecosystem in the pharmaceutical sector. It is a subsidiary of Beijing Huabin Licheng Technology Co., Ltd.

September 16,GigaCeuticals Completes Multi-Million RMB Angel Round of Financing, with Investors Including Innocore Angel Fund and Intelligent Intelligence Venture CapitalGigaCeuticals is an AI-driven drug developer that leverages its proprietary deep learning algorithm systems to analyze and predict various compounds in drug development, screen for target molecules, and validate predictions through mouse experiments, thereby providing clinical trial candidate drugs to pharmaceutical R&D enterprises.

September 15,Jinxin Fertility Completes Strategic Financing; Amount Undisclosed, with Investors Including Sequoia Capital China, Warburg Pincus, WuXi AppTec, and CITIC Bank InvestmentJinxin Fertility is a provider of assisted reproductive technology (ART) services, operating three major ART centers: Chengdu Xinan, Shenzhen Zhongshan, and HRC Fertility in the United States. The company focuses on delivering comprehensive solutions for infertility in China, including services related to fertility assessment, reproductive surgery, male reproductive medicine, traditional Chinese medicine (TCM) for reproduction, recurrent miscarriage management, and assisted reproductive technologies.

Overseas Financing

On September 17, WHILL completed a $45 million Series C financing round, led by Eight Roads Ventures, SBI Investment, Innovation Network Corporation of Japan, Whiz Partners, and Daiwa Securities Group. WHILL provides smart and enjoyable mobility solutions for everyone. The company’s mission is to transform perceptions of mobility devices, such as wheelchairs and scooters, through advanced technology and intelligent design.

On September 17, Beta Bionics completed a $50 million Series B financing round, led by Eli Lilly, Novo Nordisk, and Eventide Asset Management. Beta Bionics is the developer of the world’s first bionic pancreas. The company has pledged to prioritize individuals with diabetes or other blood glucose disorders above all else.

On September 17, MIACH Orthopaedics completed a $22.5 million Series A financing round, led by Amzak Health Investors. MIACH Orthopaedics is a private company based in Boston, Massachusetts, dedicated to developing bioengineered surgical implants for connective tissue repair. The company’s initial primary focus was on the Bridge-Enhanced™ ACL Repair (BEAR™).

On September 17, Virion Therapeutics completed a $4.05 million Series A financing round, led by Robin Hood Ventures. Virion Therapeutics is a science-driven company developing innovative immunotherapies for virus-associated cancers and chronic viral infections. Its novel, highly effective vaccines, ChiVax and ChiVax-gD, can induce potent and sustainable T cell-mediated immune responses specifically targeting transfected cells, thereby enabling the treatment of common diseases with significant unmet medical needs.

On September 14, Endotronix completed a $45 million Series D financing round, led by Silicon Valley Bank. Endotronix has developed miniaturized, wireless, implantable pressure sensors. The sensor is implanted as part of an interventional cardiovascular procedure and connects to external measurement instruments. Founded in 2007, Endotronix is headquartered in East Peoria, Illinois.

On September 14, Myra completed a financing round of 8.75 million Indian rupees (approximately $120,000), led by Matrix Partners, Matrix Partners India, Dream Incubator, and Times Internet. Myra believes in a healthier tomorrow where people no longer have to bear physical or financial pain. Headquartered in Bangalore, the company operates its own warehouses to ensure the highest quality medications for customers without compromising their experience. Myra was named one of the 17 startups to watch in 2017.

On September 14, MGB Biopharma completed a £1.3 million financing round, led by Innovate UK and Archangels. MGB Biopharma is a biopharmaceutical company dedicated to developing a novel class of anti-infective agents based on DNA Minor Groove Binder (MGB) compounds. The company boasts an experienced team from the pharmaceutical and biotechnology sectors, committed to developing small-molecule drugs with specific antibacterial efficacy against drug-resistant bacteria. Unlike new drugs typically derived from modifications of existing medications, the company has opted for a new class of antibacterial agents. MGB Biopharma believes that this novel mechanism of action will prove highly effective against bacteria.